Heidelberg Pharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Andreas Pahl
Chief executive officer
€450.7k
Total compensation
| CEO salary percentage | 53.3% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.7yrs |
| Board average tenure | 12.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Aug 31 2024 | n/a | n/a | -€19m |
| May 31 2024 | n/a | n/a | -€13m |
| Feb 29 2024 | n/a | n/a | -€18m |
| Nov 30 2023 | €451k | €240k | -€20m |
| Aug 31 2023 | n/a | n/a | -€22m |
| May 31 2023 | n/a | n/a | -€27m |
| Feb 28 2023 | n/a | n/a | -€19m |
| Nov 30 2022 | €328k | €240k | -€20m |
| Aug 31 2022 | n/a | n/a | -€21m |
| May 31 2022 | n/a | n/a | -€22m |
| Feb 28 2022 | n/a | n/a | -€27m |
| Nov 30 2021 | €442k | €240k | -€26m |
| Aug 31 2021 | n/a | n/a | -€25m |
| May 31 2021 | n/a | n/a | -€22m |
| Feb 28 2021 | n/a | n/a | -€20m |
| Nov 30 2020 | €295k | €207k | -€18m |
| Aug 31 2020 | n/a | n/a | -€17m |
| May 31 2020 | n/a | n/a | -€15m |
| Feb 29 2020 | n/a | n/a | -€12m |
| Nov 30 2019 | €288k | €200k | -€10m |
| Aug 31 2019 | n/a | n/a | -€10m |
| May 31 2019 | n/a | n/a | -€11m |
| Feb 28 2019 | n/a | n/a | -€12m |
| Nov 30 2018 | €286k | €200k | -€12m |
| Aug 31 2018 | n/a | n/a | -€11m |
| May 31 2018 | n/a | n/a | -€11m |
| Feb 28 2018 | n/a | n/a | -€11m |
| Nov 30 2017 | €241k | €171k | -€11m |
Compensation vs Market: Andreas's total compensation ($USD476.14K) is above average for companies of similar size in the UK market ($USD353.74K).
Compensation vs Earnings: Andreas's compensation has increased whilst the company is unprofitable.
CEO
Andreas Pahl
less than a year
Tenure
€450,663
Compensation
Prof. Dr. Andreas Pahl is Chief Executive Officer & Spokesman of the Executive Board at Heidelberg Pharma AG since February 1, 2024 and had been its Chief Scientific Officer and Member of the Executive Man...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Spokesman of the Executive Board | less than a year | €450.66k | no data | |
| Chief Financial Officer | 1.5yrs | €398.63k | no data | |
| Chief Operating Officer | 1.8yrs | no data | no data | |
| Director Corporate Communication | no data | no data | no data | |
| Chief Medical Officer | 3.7yrs | no data | no data | |
| Chief Business Officer | no data | no data | no data |
1.7yrs
Average Tenure
Experienced Management: 0QW5's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of the Supervisory Board | 19.6yrs | €18.00k | no data | |
| Deputy Chairman of the Supervisory Board | 24.8yrs | €38.00k | no data | |
| Chairman of Supervisory Board | 14.5yrs | €49.50k | no data | |
| Member of the Supervisory Board | 12.5yrs | €21.75k | no data | |
| Deputy Chairman of Supervisory Board | 9.3yrs | €39.00k | no data | |
| Member of Supervisory Board | 2.4yrs | €21.00k | no data | |
| Member of Supervisory Board | 1.5yrs | €9.96k | no data |
12.5yrs
Average Tenure
59.5yo
Average Age
Experienced Board: 0QW5's board of directors are seasoned and experienced ( 12.5 years average tenure).